Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, Placebo Controlled, Ascending Dose, Randomized Phase 1B/2A Study, Investigating Safety, Tolerability, PK/PD of FE 203799 in Lymphoma Patients, Undergoing Myeloablative Chemotherapy Before Autologous Transplantation

Trial Profile

Double-blind, Placebo Controlled, Ascending Dose, Randomized Phase 1B/2A Study, Investigating Safety, Tolerability, PK/PD of FE 203799 in Lymphoma Patients, Undergoing Myeloablative Chemotherapy Before Autologous Transplantation

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 02 Nov 2018

At a glance

  • Drugs Apraglutide (Primary)
  • Indications Gastrointestinal disorders
  • Focus Adverse reactions
  • Sponsors GLyPharma Therapeutic
  • Most Recent Events

    • 24 Oct 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as per Business decision.
    • 31 Aug 2018 Biomarkers information updated
    • 05 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top